No Data
No Data
We're Hopeful That Enliven Therapeutics (NASDAQ:ELVN) Will Use Its Cash Wisely
BTIG Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $42
Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36
Strong Buy Recommendation for Enliven Therapeutics: Promising Efficacy and Strategic Positioning in CML Market